 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI  Get Free Report) has received a consensus recommendation of Buy from the six analysts that are presently covering the stock...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from Analysts

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE...

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill  Containing Ustekinumab Biosimilar, CT-P43)

- Two preclinical studies of RaniPill HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical...

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ( Rani Therapeutics or Rani ) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

Rani Therapeutics to Participate in September Investor Conferences

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI Get Free Report) have been assigned an average recommendation of Buy from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $20.25 Consensus Price Target from Analysts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI Free Report) Investment analysts at Wedbush dropped their Q3 2023 earnings estimates for shares of Rani Therapeutics in a report released on Wednesday, August 16th. Wedbush analyst A. Argyrides now expects that the company will earn ($0.37) per share for...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Forecasted to Post Q3 2023 Earnings of ($0.37) Per Share

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI  Free Report)  Investment analysts at Wedbush lowered their Q3 2023 EPS estimates for Rani Therapeutics in a note issued to investors on Wednesday, August 16th. Wedbush analyst A. Argyrides now expects that the company will earn ($0.37) per...

Wedbush Equities Analysts Cut Earnings Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI Free Report) Research analysts at HC Wainwright reduced their Q3 2023 earnings per share estimates for Rani Therapeutics in a report released on Monday, August 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.84) per ...

Equities Analysts Offer Predictions for Rani Therapeutics Holdings, Inc.'s Q3 2023 Earnings (NASDAQ:RANI)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH Research Rep... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Reviva Pharmaceuticals Holdings (RVPH Research ...

Analysts' Top Healthcare Picks: Reviva Pharmaceuticals Holdings (RVPH), Rani Therapeutics Holdings (RANI)

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of ...

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Watchers	306
52-Wk Low	$2.56
52-Wk High	$10.80

Market Cap	$70.98M
Volume (M)	17,485.00
52-Wk High	$10.80
52-Wk Low	$2.56

RANI Rani Therapeutics Holdings Inc - Ordinary Shares Class A

About

Feed

News

Earnings

Fundamentals